Tumor lysis syndrome: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
| BugRequired= | | BugRequired= | ||
}} | }} | ||
{{ICD10 category| | {{ICD10 category|Endocrine disorder}}{{ICD10 category|Metabolic/nutrition}}{{ICD10 category|Neoplastic}} | ||
{{ICD10 category|Neoplastic}} | |||
== Additional Info == | == Additional Info == | ||
Revision as of 14:05, 18 October 2018
| ICD10 Diagnosis | |
| Dx: | Tumor lysis syndrome |
| ICD10 code: | E88.3 |
| Pre-ICD10 counterpart: | Tumor Lysis Syndrome |
| Charlson/ALERT Scale: | none |
| APACHE Como Component: | none |
| APACHE Acute Component: | 2019-0: Renal/Metabolic NOS, 2019-0: Metabolic/Renal NOS |
| Start Date: | |
| Stop Date: | |
| Data Dependencies(Reports/Indicators/Data Elements): | No results |
| External ICD10 Documentation | |
This diagnosis is a part of ICD10 collection.
Additional Info
Alternate ICD10s to consider coding instead or in addition
- Metabolic disorder, NOS
- Antineoplastic drug (chemotherapy) used appropriately, adverse effect (reaction, allergy, hypersensitivity)
Candidate Combined ICD10 codes
Related CCI Codes
Related Articles
Show all ICD10 Subcategories